Skip directly to content

Dutch ELIGIBILITY

Eligibility criteria

ASPIRE I-CRP is open to applications from all clinical practitioners and scientists working in the Netherlands who:

(i) Do not directly work for Pfizer or any other pharmaceutical company.
(ii) Are not members of the current ASPIRE I-CRP Grant Awarding Committee.1
(iii) And hold a medical or pharmacy degree or a PhD.

1Current Grant Awarding Committee members cannot be an applicant or co-applicant on a proposal
submitted for the program, nor be an author on any publication ensuing from the award of funding by the program. The committee members will not participate in the review of any proposal that poses a conflict of interest. Proposals received from current Grant Awarding Committee members’ institutions will still be allowed but the scoring and review decisions of these proposals will be made by the committee excluding the potentially conflicted member.

Applications should also:

(i) Focus on clinical research that will impact patient outcomes.
(ii) Relate to an area aligned to the program’s areas of therapeutic focus (Rheumatoid Arthritis,
Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis or Juvenile Idiopathic Arthritis),
but are not necessarily expected to involve treatment with etanercept

Pfizer reserves the right not to support projects that fall outside of Pfizer’s internal compliance policies and procedures or those that replicate existing research. .

Additionally, we are unable to fund direct comparative treatment studies primarily involving competitor products, studies where the risk/benefit ratio to patients is not obviously positive, or studies that involve the use of compounds in development. .

Applicants whose projects are selected by the grant awarding committee will be awarded the grant upon the condition that:

(i) the contract between Pfizer and the respective institution is agreed within 3 months of receiving
notification of the award
(ii) and Pfizer has received documentation confirming approval by the relevant ethics committee and
the local Research and Development department as appropriate within 3 months of receiving notification of the award. .

OTHER FUNDINGS

No other government, non-governmental, or industry-sponsored projects may cover the same work scope as the grant application to the ASPIRE I-CRP. However, an I-CRP grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the Applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.

Once awarded, an ASPIRE grant cannot be amended upwards with additional funding support from Pfizer (via the standard IIR process or separate competitive grant program), nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the external review committee be provided. If supplemental funding is required, it must be secured from sources outside of Pfizer. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer supported competitive grant program. However, if drug supply is needed solely (due to statistical or protocol specific reasons – example – pt withdrawal, early dropout etc.) this will be considered.

QUESTIONS

Jolanda.vanBodegraven@pfizer.com